Thiel fellow on how longevity can fix biotech - Lada Nuzhna скачать в хорошем качестве

Thiel fellow on how longevity can fix biotech - Lada Nuzhna

Lada Nuzhna is a researcher and founder driven by two questions: how did we get here, and how do we stay. Lada dropped out of college to pursue her biology research as a Thiel fellow, and to co-found Impetus Grants which funds breakthrough longevity science. Through Impetus, she has allocated over $34M to fund some of the most ambitious projects and clinical trials in aging. She is now developing a new therapeutic modality to target diseases of aging through her startup, General Control. In addition to her work as an investor and founder, Lada is a prolific author of short-form and long-form content, which you can find through her Twitter (https://x.com/ladanuzhna) and Blog (https://www.ladanuzhna.xyz). 0:00:00 Intro 00:02:12 First principles biology 00:06:43 We don’t collect enough of the right data for aging 00:09:41 Impetus grants funds novel rather than incremental science 00:12:52 Academic funding environment is dramatically changing 00:16:08 Incentives are misaligned to fund longevity therapies in the US 00:19:49 Are GLP-1s a longevity drug? 00:21:49 Lada’s startup: scalpel-like epigenetic editing 00:35:08 Everyone is using aging clocks but we don’t know what they’re doing 00:42:10 We don’t have good animal models for aging 00:45:54 The two types of longevity companies 00:48:30 Where are all the trillion-dollar biotechs 00:52:07 Will AI help us develop the next blockbusters? 00:54:52 Platform biotechs 00:59:04 Lightning round